NEW YORK (GenomeWeb) – One of the co-founders of Beeologics — a developer of RNAi treatments for key bee disorders that was acquired in 2011 by Monsanto — has created a new business focused on using the gene-silencing technology to tackle a major threat to citrus crops and mosquito-borne diseases.

Called Forrest Innovations, the company was established by Nitzan Paldi, who in 2007 co-founded Beeologics to use RNAi to combat Israeli acute paralysis virus, a bee disease linked to colony collapse disorder, and the honey bee parasite Varroa destructor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.